Which has better valuation & earnings, WAY or DOCS?

Doximity has lower revenue, but higher earnings than Waystar. Doximity is trading at a lower price-to-earnings ratio than Waystar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Waystar $1.10B 4.62 $112.09M $0.70 37.83 Doximity $644.86M 7.93 $196.05M $0.85 33.75

Is WAY or DOCS more profitable?

Doximity has a net margin of 25.48% compared to Waystar's net margin of 11.18%. Doximity's return on equity of 18.06% beat Waystar's return on equity. Company Net Margins Return on Equity Return on Assets Waystar 11.18% 7.03% 4.75% Doximity 25.48% 18.06% 15.40%

Does the media favor WAY or DOCS?

In the previous week, Doximity had 26 more articles in the media than Waystar. MarketBeat recorded 29 mentions for Doximity and 3 mentions for Waystar. Waystar's average media sentiment score of 0.64 beat Doximity's score of 0.13 indicating that Waystar is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Waystar 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Doximity 2 Very Positive mention(s) 4 Positive mention(s) 20 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, DOCS or HTFL?

Doximity has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Doximity $644.86M 7.93 $196.05M $0.85 33.75 Heartflow $176.03M 25.79 -$116.79M -$1.83 N/A

Is DOCS or HTFL more profitable?

Doximity has a net margin of 25.48% compared to Heartflow's net margin of -55.82%. Doximity's return on equity of 18.06% beat Heartflow's return on equity. Company Net Margins Return on Equity Return on Assets Doximity 25.48% 18.06% 15.40% Heartflow -55.82% -23.52% -18.66%

Does the media refer more to DOCS or HTFL?

In the previous week, Doximity had 25 more articles in the media than Heartflow. MarketBeat recorded 29 mentions for Doximity and 4 mentions for Heartflow. Doximity's average media sentiment score of 0.13 beat Heartflow's score of -0.03 indicating that Doximity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Doximity 2 Very Positive mention(s) 4 Positive mention(s) 20 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Heartflow 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, DOCS or SDGR?

Doximity has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Doximity $644.86M 7.93 $196.05M $0.85 33.75 Schrodinger $255.87M 9.41 -$103.26M -$0.74 N/A

Is DOCS or SDGR more profitable?

Doximity has a net margin of 25.48% compared to Schrodinger's net margin of -20.98%. Doximity's return on equity of 18.06% beat Schrodinger's return on equity. Company Net Margins Return on Equity Return on Assets Doximity 25.48% 18.06% 15.40% Schrodinger -20.98% -16.37% -8.19%

Does the media refer more to DOCS or SDGR?

In the previous week, Doximity had 26 more articles in the media than Schrodinger. MarketBeat recorded 29 mentions for Doximity and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.77 beat Doximity's score of 0.13 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Doximity 2 Very Positive mention(s) 4 Positive mention(s) 20 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, DOCS or CERT?

Doximity has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Doximity $644.86M 7.93 $196.05M $0.85 33.75 Certara $418.84M 3.67 -$1.60M -$0.45 N/A

Is DOCS or CERT more profitable?

Doximity has a net margin of 25.48% compared to Certara's net margin of -16.75%. Doximity's return on equity of 18.06% beat Certara's return on equity. Company Net Margins Return on Equity Return on Assets Doximity 25.48% 18.06% 15.40% Certara -16.75% 3.86% 2.65%

Does the media refer more to DOCS or CERT?

In the previous week, Doximity had 25 more articles in the media than Certara. MarketBeat recorded 29 mentions for Doximity and 4 mentions for Certara. Certara's average media sentiment score of 0.33 beat Doximity's score of 0.13 indicating that Certara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Doximity 2 Very Positive mention(s) 4 Positive mention(s) 20 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Certara 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, GDRX or DOCS?

Doximity has lower revenue, but higher earnings than GoodRx. Doximity is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.44 $30.44M $0.04 84.00 Doximity $644.86M 7.93 $196.05M $0.85 33.75

Is GDRX or DOCS more profitable?

Doximity has a net margin of 25.48% compared to GoodRx's net margin of 2.07%. Doximity's return on equity of 18.06% beat GoodRx's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.07% 7.22% 2.53% Doximity 25.48% 18.06% 15.40%

Does the media favor GDRX or DOCS?

In the previous week, Doximity had 25 more articles in the media than GoodRx. MarketBeat recorded 29 mentions for Doximity and 4 mentions for GoodRx. GoodRx's average media sentiment score of 0.51 beat Doximity's score of 0.13 indicating that GoodRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GoodRx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Doximity 2 Very Positive mention(s) 4 Positive mention(s) 20 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Doximity (DOCS) Competitors

$28.69 +0.76 (+2.71%)

Closing price 10/5/2026 03:59 PM Eastern

Extended Trading

$29.29 +0.60 (+2.09%)

As of 05:01 AM Eastern

Compare

DOCS vs. WAY, HTFL, SDGR, CERT, and GDRX

Should you buy Doximity stock or one of its competitors? Doximity's main competitors and comparable companies include Waystar (WAY), Heartflow (HTFL), Schrodinger (SDGR), Certara (CERT), and GoodRx (GDRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Doximity compare to Waystar?

Waystar (NASDAQ:WAY) and Doximity (NYSE:DOCS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

87.2% of Doximity shares are held by institutional investors. 3.5% of Waystar shares are held by insiders. Comparatively, 31.8% of Doximity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Doximity has lower revenue, but higher earnings than Waystar. Doximity is trading at a lower price-to-earnings ratio than Waystar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Waystar	$1.10B	4.62	$112.09M	$0.70	37.83
Doximity	$644.86M	7.93	$196.05M	$0.85	33.75

Waystar currently has a consensus target price of $34.67, indicating a potential upside of 30.92%. Doximity has a consensus target price of $31.95, indicating a potential upside of 11.39%. Given Waystar's stronger consensus rating and higher probable upside, analysts plainly believe Waystar is more favorable than Doximity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Waystar	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Doximity	3 Sell rating(s)	14 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.24

Waystar has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market. Comparatively, Doximity has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

In the previous week, Doximity had 26 more articles in the media than Waystar. MarketBeat recorded 29 mentions for Doximity and 3 mentions for Waystar. Waystar's average media sentiment score of 0.64 beat Doximity's score of 0.13 indicating that Waystar is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Waystar	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Doximity	2 Very Positive mention(s)	4 Positive mention(s)	20 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Doximity has a net margin of 25.48% compared to Waystar's net margin of 11.18%. Doximity's return on equity of 18.06% beat Waystar's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Waystar	11.18%	7.03%	4.75%
Doximity	25.48%	18.06%	15.40%

Summary

Doximity beats Waystar on 10 of the 17 factors compared between the two stocks.

How does Doximity compare to Heartflow?

Doximity (NYSE:DOCS) and Heartflow (NASDAQ:HTFL) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

In the previous week, Doximity had 25 more articles in the media than Heartflow. MarketBeat recorded 29 mentions for Doximity and 4 mentions for Heartflow. Doximity's average media sentiment score of 0.13 beat Heartflow's score of -0.03 indicating that Doximity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Doximity	2 Very Positive mention(s)	4 Positive mention(s)	20 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heartflow	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Doximity has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Doximity	$644.86M	7.93	$196.05M	$0.85	33.75
Heartflow	$176.03M	25.79	-$116.79M	-$1.83	N/A

Doximity has a net margin of 25.48% compared to Heartflow's net margin of -55.82%. Doximity's return on equity of 18.06% beat Heartflow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Doximity	25.48%	18.06%	15.40%
Heartflow	-55.82%	-23.52%	-18.66%

87.2% of Doximity shares are held by institutional investors. 31.8% of Doximity shares are held by insiders. Comparatively, 7.7% of Heartflow shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Doximity has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Heartflow has a beta of 2.73, indicating that its share price is 173% more volatile than the broader market.

Doximity presently has a consensus target price of $31.95, suggesting a potential upside of 11.39%. Heartflow has a consensus target price of $46.25, suggesting a potential downside of 11.42%. Given Doximity's higher probable upside, equities research analysts clearly believe Doximity is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Doximity	3 Sell rating(s)	14 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.24
Heartflow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Doximity beats Heartflow on 12 of the 16 factors compared between the two stocks.

How does Doximity compare to Schrodinger?

Doximity (NYSE:DOCS) and Schrodinger (NASDAQ:SDGR) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Doximity had 26 more articles in the media than Schrodinger. MarketBeat recorded 29 mentions for Doximity and 3 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.77 beat Doximity's score of 0.13 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Doximity	2 Very Positive mention(s)	4 Positive mention(s)	20 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Doximity has a net margin of 25.48% compared to Schrodinger's net margin of -20.98%. Doximity's return on equity of 18.06% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Doximity	25.48%	18.06%	15.40%
Schrodinger	-20.98%	-16.37%	-8.19%

87.2% of Doximity shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 31.8% of Doximity shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Doximity has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Doximity	$644.86M	7.93	$196.05M	$0.85	33.75
Schrodinger	$255.87M	9.41	-$103.26M	-$0.74	N/A

Doximity has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

Doximity presently has a consensus target price of $31.95, suggesting a potential upside of 11.39%. Schrodinger has a consensus target price of $20.80, suggesting a potential downside of 36.20%. Given Doximity's higher possible upside, analysts plainly believe Doximity is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Doximity	3 Sell rating(s)	14 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.24
Schrodinger	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Doximity beats Schrodinger on 13 of the 17 factors compared between the two stocks.

How does Doximity compare to Certara?

Doximity (NYSE:DOCS) and Certara (NASDAQ:CERT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Doximity has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Certara has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

In the previous week, Doximity had 25 more articles in the media than Certara. MarketBeat recorded 29 mentions for Doximity and 4 mentions for Certara. Certara's average media sentiment score of 0.33 beat Doximity's score of 0.13 indicating that Certara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Doximity	2 Very Positive mention(s)	4 Positive mention(s)	20 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Certara	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Doximity has a net margin of 25.48% compared to Certara's net margin of -16.75%. Doximity's return on equity of 18.06% beat Certara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Doximity	25.48%	18.06%	15.40%
Certara	-16.75%	3.86%	2.65%

87.2% of Doximity shares are held by institutional investors. Comparatively, 74.0% of Certara shares are held by institutional investors. 31.8% of Doximity shares are held by company insiders. Comparatively, 1.1% of Certara shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Doximity currently has a consensus price target of $31.95, suggesting a potential upside of 11.39%. Certara has a consensus price target of $8.45, suggesting a potential downside of 16.09%. Given Doximity's higher possible upside, equities analysts plainly believe Doximity is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Doximity	3 Sell rating(s)	14 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.24
Certara	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Doximity has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Doximity	$644.86M	7.93	$196.05M	$0.85	33.75
Certara	$418.84M	3.67	-$1.60M	-$0.45	N/A

Summary

Doximity beats Certara on 13 of the 16 factors compared between the two stocks.

How does Doximity compare to GoodRx?

GoodRx (NASDAQ:GDRX) and Doximity (NYSE:DOCS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

63.8% of GoodRx shares are owned by institutional investors. Comparatively, 87.2% of Doximity shares are owned by institutional investors. 5.9% of GoodRx shares are owned by insiders. Comparatively, 31.8% of Doximity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Doximity had 25 more articles in the media than GoodRx. MarketBeat recorded 29 mentions for Doximity and 4 mentions for GoodRx. GoodRx's average media sentiment score of 0.51 beat Doximity's score of 0.13 indicating that GoodRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Doximity	2 Very Positive mention(s)	4 Positive mention(s)	20 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Doximity has lower revenue, but higher earnings than GoodRx. Doximity is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.44	$30.44M	$0.04	84.00
Doximity	$644.86M	7.93	$196.05M	$0.85	33.75

GoodRx has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Doximity has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Doximity has a net margin of 25.48% compared to GoodRx's net margin of 2.07%. Doximity's return on equity of 18.06% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.07%	7.22%	2.53%
Doximity	25.48%	18.06%	15.40%

GoodRx currently has a consensus target price of $4.23, suggesting a potential upside of 25.81%. Doximity has a consensus target price of $31.95, suggesting a potential upside of 11.39%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Doximity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08
Doximity	3 Sell rating(s)	14 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.24

Summary

Doximity beats GoodRx on 12 of the 17 factors compared between the two stocks.

Get Doximity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOCS vs. The Competition

Export

Metric	Doximity	Healthcare Technology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$4.98B	$1.74B	$7.14B	$22.78B
Dividend Yield	N/A	3.95%	2.53%	3.72%
P/E Ratio	33.75	21.04	274.34	27.90
Price / Sales	7.93	88.51	614.18	20.36
Price / Cash	22.53	31.81	27.22	19.11
Price / Book	5.53	6.23	11.34	4.70
Net Income	$196.05M	-$18.66M	$3.49B	$1.07B
7 Day Performance	8.14%	0.41%	-1.27%	0.47%
1 Month Performance	8.96%	-0.50%	-5.94%	-5.36%
1 Year Performance	N/A	-21.17%	7.29%	5.39%

Doximity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOCS Doximity	3.8575 of 5 stars	$28.69 +2.7%	$31.95 +11.4%	N/A	$4.98B	$644.86M	33.75	880	Trending News
WAY Waystar	4.2886 of 5 stars	$25.10 +1.2%	$34.67 +38.1%	-31.5%	$4.76B	$1.10B	35.47	1,700	Positive News
HTFL Heartflow	1.6651 of 5 stars	$49.74 +0.8%	$46.25 -7.0%	+38.7%	$4.29B	$176.03M	N/A	843	Analyst Upgrade
SDGR Schrodinger	1.2243 of 5 stars	$29.81 -1.6%	$20.80 -30.2%	+58.3%	$2.23B	$255.87M	N/A	850
CERT Certara	1.4792 of 5 stars	$9.32 -0.5%	$8.45 -9.3%	-23.0%	$1.43B	$418.84M	N/A	1,576	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DOCS) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Doximity (DOCS) Competitors